FindTrial
Sign In

EFFECT OF TESTOSTERONE HORMONAL THERAPY IN GENERAL WELL-BEING OF TRANSMALE (FEMALE TO MALE)INDIVIDUALS

GENDER AFFIRMING CROSS-SEX HORMONAL THERAPY IN TRANSMALES- A COMPARATIVE STUDY USING TWO DIFFERENT TESTOSTERONE FORMULATIONS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052920
Enrollment
50
Registered
2023-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Testosterone: Two different formulations of Testosterone- testovirion (100/250mg) intramuscularly once in 3 weeks or Testosterone undeconate 1000mg given intramuscularly once in 3 mont

Sponsors

Government Rajaji hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult females with gender dysphoria Treatment naïve transmales

Exclusion criteria

Exclusion criteria: Patients who are already on testosterone therapy Age less than 18 years with gender dysphoria Patients with comorbid conditions like hypertension, diabetes, cardiovascular disease Patients on Calcium/ Vitamin D / bisphosphonates Contraindications to testosterone therapy

Design outcomes

Primary

MeasureTime frame
Alleviation of gender dysphoria Increase in facial hair, body hair, clitoromegaly Increase in lean body mass, decrease in fat mass Increase in bone mineral density Increase in testosterone levels Timepoint: at baseline, 6 months and 1 year—

Secondary

MeasureTime frame
To compare two different formulations of testosterone in getting the desired outcomesTimepoint: at baseline, 6 months and 1 year—

Countries

India

Contacts

Public ContactDr Sinju Sankar P

Madurai Medical College

drsridharjipmer@gmail.com9995632286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026